Zuyan Fan

Zuyan Fan

Auto-generated profile, based on publicly available information

Zuyan Fan

Zhejiang Key Laboratory of Molecular Cancer Biology, Life Sciences Institute, Zhejiang University

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
FZFengxia Zhang
Fengxia Zhang
NJNan Jiang
Nan Jiang
YGYan Gao
Yan Gao
ZFZuyan Fan
Zuyan Fan
QLQuhuan Li
Quhuan Li
SLShuangxin Liu
Shuangxin Liu

1 April 2015 in European Journal of Oncology Nursing
Verified
Journal Article
Closed access
JLJin-Xiang Lin
Jin-Xiang Lin
ZFZu-Yan Fan
Zu-Yan Fan
QLQu Lin
Qu Lin
DWDong-Hao Wu
Dong-Hao Wu
XWXiang-Yuan Wu
Xiang-Yuan Wu
XWXiangbo Wan
Xiangbo Wan

24 September 2026 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
XSXiaoxian Shi
Xiaoxian Shi
ZFZuyan Fan
Zuyan Fan
MQMin Qu
Min Qu
CLChunjie Lin
Chunjie Lin
ZJZhiheng Ji
Zhiheng Ji
WSWenjing Su
Wenjing Su
Resistance to androgen receptor (AR)-targeted therapies remains a major clinical challenge in advanced prostate cancer. Here we identify follistatin (FST), TGFβ superfamily antagonist, as a key driver of AR-independence and treatment resistance. During anti-AR therapy, cancer cells progressively lose the positive feedback loop between AR and BMP signaling, leading to FST upregulation that further suppresses this circuit. FST antagonizes BMP11-dependent AR maintenance and upregulates the lineage plasticity regulator SOX9, conferring resistance to enzalutamide while promoting stem-like properties and metastatic capabilities. FST also remodels the tumor microenvironment by driving osteoclastogenesis and compromising T cell effector function. Clinically, FST inversely correlates with PSA levels and associates with poor outcomes in enzalutamide-treated patients. We developed FST-Trap, which effectively neutralizes FST, resensitizes resistant tumors to AR-targeted therapy, and enhances immunotherapy efficacy. This establishes FST as both a biomarker and therapeutic target for AR-independent prostate cancer.